Spero Therapeutics, Inc. (SPRO) P/E Ratio History
UndervaluedTrading at 7.9x vs 5Y avg 15.2x · 38th percentile · Below historical baseline · Data 2023–2026
Loading P/E history...
P/E Ratio Analysis
As of October 3, 2026, Spero Therapeutics, Inc. (SPRO) trades at a price-to-earnings ratio of 7.9x, with a stock price of $1.19 and trailing twelve-month earnings per share of $0.13.
The current P/E is 48% below its 5-year average of 15.2x. Over the past five years, SPRO's P/E has ranged from a low of 3.3x to a high of 41.4x, placing the current valuation at the 38th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.2x, SPRO trades at a 66% discount to its sector peers. The sector includes 225 companies with P/E ratios ranging from 0.0x to 190.0x.
Relative to the broader market, SPRO trades at a notable discount to the S&P 500 median P/E of 24.5x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our SPRO DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
SPRO Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
SPRO P/E vs Peers
Vaccines and Infectious Disease peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $883M | 8.3Lowest | - | +279%Best | |
| $3B | 8.7 | - | +68% | |
| $158B | 20.4 | - | -4% | |
| $356B | 19.8 | 0.93Best | +8% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
SPRO Historical P/E Data (2023–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q2 | - | $2.21 | $0.11 | 20.1x | +33% |
| FY2026 Q1 | - | $2.34 | $0.24 | 9.8x | -36% |
| FY2025 Q4 | Dec 31 2025 | $2.33 | $0.12 | 19.5x | +28% |
| FY2024 Q3 | Sep 30 2024 | $1.34 | $0.07 | 19.1x | +26% |
| FY2024 Q2 | Jun 30 2024 | $1.30 | $0.33 | 3.9x | -74% |
| FY2024 Q1 | Mar 31 2024 | $1.72 | $0.43 | 4.0x | -74% |
| FY2023 Q4 | Dec 31 2023 | $1.47 | $0.44 | 3.3x | -78% |
| FY2023 Q3 | Sep 30 2023 | $1.21 | $0.03 | 41.4x | +174% |
Average P/E for displayed period: 15.2x
SPRO Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
3+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
SPRO — Frequently Asked Questions
Quick answers to the most common questions about buying SPRO stock.
What is SPRO's P/E ratio?
Spero Therapeutics, Inc. (SPRO) trailing twelve-month P/E ratio is 7.9x, based on TTM diluted EPS of $0.13. The 5-year average P/E is 15.2x and the historical range spans 3.3x to 41.4x.
Is SPRO stock overvalued or undervalued?
SPRO trades at 7.9x P/E, below its 5-year average of 15.2x. At the 38th percentile of its historical range (3.3x–41.4x), the stock is priced at a discount to its own history.
Is SPRO stock expensive?
No, SPRO is not expensive on a historical basis. The current P/E of 7.9x is below the 5-year average of 15.2x and sits at the 38th percentile of its valuation range.
What is SPRO's historical P/E range?
Over the past 5 years, SPRO's P/E ratio has ranged from 3.3x to 41.4x, with a median of 19.1x and an average of 15.2x. The current P/E of 7.9x places the stock at the 38th percentile of this range. Full historical data spans 2023–2026.
How does SPRO's P/E compare to the S&P 500?
SPRO trades at 7.9x P/E versus the S&P 500 median of 24.5x. The 68% discount to the market suggests lower growth expectations or perceived higher risk.
How does SPRO's valuation compare to Healthcare peers?
Spero Therapeutics, Inc. P/E of 7.9x compares to the Healthcare sector median of 23.2x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is SPRO's PEG ratio?
SPRO PEG ratio is N/A, based on a P/E of 7.9x and EPS growth of 111.8%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is SPRO's earnings yield?
SPRO earnings yield is 12.61%, the inverse of its 7.9x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.